Virologic response in patients with chronic hepatitis C after treatment with interferon 2b alone or in combination with ribavirin.

被引：0
|
作者：
Futuh, ARA
Solayman, AEM
El Hendawy, SM
El Hadad, SM
Omar, MM
Kamel, MM
机构：
[1] Mansoura Int Hosp, Mansoura, Egypt
[2] Asuit Univ, Asuit, Egypt
[3] Univ Mansoura, Mansoura, Egypt
[4] Ein Shams Univ, Cairo, Egypt
[5] Theodor Bilharse Res Inst, Cairo, Egypt
[6] Ein Shams Univ, Cairo, Egypt
来源：
HEPATOLOGY | 2002年 / 36卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1706
引用
收藏
页码：589A / 589A
页数：1
相关论文
共 50 条
  • [31] Rheumatic manifestations in children with chronic C virus hepatitis treated with interferon-α 2b plus ribavirin.
    Molano, A
    Gorbea, MD
    Fuentes, J
    Fraga, A
    Medina, F
    ARTHRITIS AND RHEUMATISM, 2000, 43 (09): : S191 - S191
  • [32] Hepatic steatosis is a predictor of poor response to interferon α-2b and ribavirin combination therapy in Japanese patients with chronic hepatitis C
    Yaginuma, Reiko
    Ikejima, Kenichi
    Okumura, Kyoko
    Kon, Kazuyoshi
    Suzuki, Satoko
    Takei, Yoshiyuki
    Sato, Nobuhiro
    HEPATOLOGY RESEARCH, 2006, 35 (01) : 19 - 25
  • [33] Predictors of virologic response in combination therapy with interferon (IFN) alfa 2B plus ribavirin of recurrent hepatitis C after liver transplantation (LT)
    Lavezzo, B
    Franchello, A
    Smedile, A
    Cocchis, D
    David, E
    Barbui, A
    Ottobrelli, A
    Fadda, M
    Brunati, A
    Salizzoni, M
    Rizzetto, M
    JOURNAL OF HEPATOLOGY, 2003, 38 : 5 - 5
  • [34] Ribavirin and interferon-α-2b combination treatment of chronic hepatitis C in patients with haemophilia and other clotting disorders.
    Fried, R
    Meili, E
    Peter, K
    Hartmann, S
    Tsakiris, D
    Fried, C
    Egger, H
    Zanni, M
    Marbet, G
    GASTROENTEROLOGY, 1999, 116 (04) : A1212 - A1212
  • [35] Daily or three times a week interferon alfa-2b in combination with ribavirin or interferon alone for the treatment of patients with chronic hepatitis C
    de Lédinghen, V
    Trimoulet, P
    Winnock, M
    Foucher, J
    Bourlière, M
    Desmorat, H
    Canva, V
    Capron, D
    Lévy, S
    Mion, F
    Mannant, PR
    Chêne, G
    Fleury, H
    Couzigou, P
    Bernard, PH
    JOURNAL OF HEPATOLOGY, 2002, 36 (05) : 672 - 680
  • [36] Risk factors for retinopathy associated with interferonα-2b and ribavirin combination therapy in patients with chronic hepatitis C
    Chiaki Okuse
    Hiroshi Yotsuyanagi
    Yoshihiko Nagase
    Yuhtaro Kobayashi
    Kiyomi Yasuda
    Kazuhiko Koike
    Shiro Iino
    Michihiro Suzuki
    Fumio Itoh
    World Journal of Gastroenterology, 2006, (23) : 3756 - 3759
  • [37] Risk factors for retinopathy associated with interferon α-2b and ribavirin combination therapy in patients with chronic hepatitis C
    Okuse, Chiaki
    Yotsuyanagi, Hiroshi
    Nagase, Yoshihiko
    Kobayashi, Yuhtaro
    Yasuda, Kiyomi
    Koike, Kazuhiko
    Iino, Shiro
    Suzuki, Michihiro
    Itoh, Fumio
    WORLD JOURNAL OF GASTROENTEROLOGY, 2006, 12 (23) : 3756 - 3759
  • [38] Cost effectiveness of pegylated interferon alpha 2b and ribavirin combination in chronic hepatitis C
    Poynard, T
    GUT, 2003, 52 (10) : 1532 - 1532
  • [39] Cost effectiveness of interferon α2b combined with ribavirin for the treatment of chronic hepatitis C
    Younossi, ZM
    Singer, ME
    McHutchison, JG
    Shermock, KM
    HEPATOLOGY, 1999, 30 (05) : 1318 - 1324
  • [40] Treatment of chronic hepatitis C in HIV-infected patients with interferon α-2b plus ribavirin
    Pérez-Olmeda, M
    Soriano, V
    Asensi, V
    Morales, D
    Romero, M
    Ochoa, A
    Sánchez-Montero, F
    Santin, M
    Guardiola, J
    Blanch, J
    Núñez, M
    Jiménez-Nácher, I
    García-Samaniego, J
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2003, 19 (12) : 1083 - 1089
12345